Parvovirus infection and pregnancy

Ana Duminica-Turcu¹, Radu Botezatu¹², Corina Gica¹, Gheorghe Peltecu¹², Nicolae Gica¹², Mihaela Demetrian¹, Anca Maria Panaitescu¹²

¹Filantropia Clinical Hospital, Bucharest, Romania
²“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

ABSTRACT

Issues regarding parvovirus B19 infection in pregnancy continue to arouse the interest of obstetricians all over the world, the main concern focusing on maternal outcomes and fetal consequences of the intrapartum infection. Parvovirus B19 infection remains one of the main etiologies of fetal anemia and non-immune hydrops, implying a high risk of neonatal demise. This high rate of maternal and neonatal morbidity entails a special attention towards the clinical manifestations and treatment of parvovirus B19 infection during pregnancy time. A systematic literature review was obtained from over 100 articles related to the chosen subject, out of which 27 articles were chosen as relevant to the above-mentioned subject.

Keywords: parvovirus B19, infection in pregnancy, fetal anemia, fetal hydrops

INTRODUCTION

Parvovirus B19 is a solely human virus, its main characteristics residing in its small dimensions, about 25 nm, hence its name “parvo” meaning “small” in Latin and unenveloped DNA feature, with a linear and single-stranded DNA (ssDNA), while erythrocytes and erythroblasts serve as the main sites of replication, having the capacity to induce anemia in prone patients [1]. There are multiple human parvoviruses, nonpathogenic such as adeno-associated viruses (AAVs) and pathogenic such as human Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1) [2]. While analyzing the serum of nine healthy blood-donors and two patients during a 1975 study, Cossart et al. discovered a different agent that could easily be mistaken for hepatitis-B antigen, later known as parvovirus B19 [3]. According to Heegaard, B19 infection clinical manifestations vary from erythema infectiosum to acute symmetric polyarthritis, red cell aplasia and chronic anemia to fetal death in utero, hydrops fetalis and congenital anemia [4]. Diversely, HBoV1 infection occupies a major place in the etiology of acute respiratory tract infections, implying rhinitis, pharyngitis, cough, dyspnea, wheezing, pneumonia, acute otitis media, fever, nausea, vomiting, and diarrhea, according to Jartti et al. [5].

TAXONOMY, VIROLOGY, AND CHARACTERISTICS OF PARVOVIRUS B19 INFECTION

Cotmore et al. studied the B19 taxonomy and stated that it originates in the Parvoviridae family and Parvovirinae and Densovirinae subfamilies, while Parvovirinae subfamily subsumes 8 genera: Protoparvovirus, Amdoparvovirus, Aveparvovirus, Bocparvovirus, Dependoparvovirus, Erythroparvovirus, Copiparvovirus, and Tetraparvovirus [6]. The parvovirus capsid compile 60 copies of the capsid (VP) proteins, in an icosahedral symmetry [7]. The covering of the capsid exhibits the main characteristics that are involved in the adherence to specific receptors, intracellular signaling, nuclear passage and egress and genome encapsidation, leading
to the immune response [8]. Parvovirus B19V infection avers a close connection to the bone marrow cells, especially the erythroid progenitor cells, including burst-forming unit-erythroid (BFU-E) and CFU-erythroid (CFU-E), the main sites of the progenitor cells being the bone marrow, umbilical or peripheral blood or fetal liver [9]. The fundamental receptor of B19V is the globoside or P antigen, which is commonly found in the human erythroid progenitors’ outer layer, its main role residing in systemic dissemination, according to Bönisch et al. [10]. Via an endosomal passage, B19V is transferred to the nucleus of the cell [11] and later to the lysosomal compartment, with the mentioning that the lysosome has the capacity to demean the viruses’ characteristics if it is not capable to abscond from the late endosome [12]. In a 2011 study, Chen et al. noted that, in order to achieve an adequate viral DNA replication, the signaling passage is modified, enlisting 3 phases: S-phase-dependent viral DNA replication, epo-dependent B19V DNA replication and hypoxia-facilitated B19V replication [13].

TRANSMISSION

Customarily, more than half of the adult population is seropositive to B19 parvovirus, with rates that reach up to 40-80%, the mean age of the acquired infection being 5 to 15 years, permanent protection being attained through IgG [14]. According to Anderson et al., in a 1985 study, nasal inoculation induced pyrexia, malaise, myalgia, itching after one week, lymphopenia and neutropenia after two weeks and rash and arthralgia up to 18 days after the infection [15]. The leading pathway in the transmission of the virus is the respiratory tract, followed by blood products [16].

Erythema infectiosum known as the fifth disease is the main clinical manifestation of B19V infection in children, leading to rash and arthralgia, prevailing in the winter and spring [17]. In patients suffering from a hematological disease, anemia, pure red blood cell aplasia (PRCA) or pancytopenia are frequently mentioned, Satake et al. noting that the viral load was not correlated to the hematological manifestations [18]. The immune response is the main feature of the parvovirus B19 infection: IgM antibody are traced 8 to 12 days after the infection, while IgG antibodies emerge a few days later [18].

MATERNAL FEATURES IN PARVOVIRUS B19 INFECTION

Stillbirth or intrauterine fetal demise are among the main complications of parvovirus B19 infection during pregnancy. Maternal exposure to B19V during pregnancy, especially in the first trimester, implies serious consequences such as spontaneous abortion [19]. More than half of the fertile adult females are seronegative for B19V antibodies, the rate of vertical transmission reaching up to 30%, while the rate of fetal demise when infection is acquired before 20 weeks of gestation reaches up to 11% as it is shown by a prospective evaluation of 1018 cases [20]. According to Lassen et al., the risk of fetal demise is higher when the infection is acquired during the first trimester [21].

An overall oedema of the fetus or newborn characterizes the fetal hydrops, frequently being associated with visceral organomegaly and with anemia as the main hematological trait. Usually, fetal thrombocytopenia, leukoerythroblastic reactions or liver inflammation are often identified [22]. The presence of the hydrops is confirmed via ultrasound, but cardiac failure is often identified. Amniocentesis and cordocentesis identify the virus, eosinophilic intranuclear inclusions and “balloon” cells being typically found [23]. Most of the times, the uterine exposure to parvovirus B19 does not imply clinical sequelae, as it is shown by a study conducted in a major diagnostic laboratory in Denmark, on a cohort of 113,228 children from parvovirus B19 seropositive mothers during pregnancy, from 1994 to 2009 [24]. Nonetheless, pure red cell aplasia remains the main complication of parvovirus B19 infection during pregnancy, with immunoglobulin infusions as a good treatment option for declining viremia and inducing remission [25]. Developmental restrictions, seizures or hydrocephalus, are a part of neurological impairment caused either by intrauterine anemia or viral load, while corneal opacification, ascites and bone injuries are a part of the generalized clinical manifestations [25]. According to Beigi et al., maternal symptoms include nonspecific respiratory tract infection manifestations [26].

TREATMENT

As fetal hydrops remains one of the main complications of parvovirus infection during pregnancy, the treatment requires a materno-fetal medicine specialist to determine Doppler assessment of umbilical venous and middle cerebral artery flow velocities and the referral to a tertiary care center. According to Markenson and Yancey study, when the fetus is before term, percutaneous umbilical blood sampling is needed in order to determine fetal hemoglobin and reticulocyte values, with or without intrauterine transfusion, while delivery should be taken into consideration for a near or at term fetus, without neglecting the important role of lung maturity which could be assessed through amniocentesis or obtained with the help of corticosteroid therapy [27].
CONCLUSIONS

Parvovirus B19 infection is a serious condition that leads to a high rate of morbidity or fetal mortality during pregnancy time. Parvovirus B19 seropositivity is found in more than half of the fertile adult women, the infection having the biggest incidence in the 5-15 years age group. Infection during pregnancy implies serious fetal outcomes such as stillbirth and fetal demise, the rate of vertical transmission reaching up to 30%. The current review article emphasizes the importance of the recognition of the parvovirus B19 infection, especially in women with a child at home with symptoms of infection, but also the importance of the general measures that could lead to limitation of the viral transmission.

Conflict of interest: none declared

Financial support: none declared

REFERENCES

1. Levy R, Weissman A, Blomberg G, Hayag ZJ. Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Surv. 1997 Apr;52(4):254-9.
2. Samulski RJ, Muzycka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol. 2011 Nov;1(1):427-51.
3. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975 Jan 11;1(7898):72-3.
4. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002 Jul;15(3):485-505.
5. Jartti T, Hedman K, Jartti L, Rusukanen O, Allander T, Söderlund-Venermo M. Human bocavirus—the first 5 years. Rev Med Virol. 2012 Jan;22(1):46-64.
6. Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, Söderlund-Venermo M, Tattersall P, Tijsen P, Gatherer D, Davison AJ. The family Parvoviridae. Arch Virol. 2014 May;159(5):1239-47.
7. Kaufmann B, Chipman PR, Kostyuchenko VA, Modrow S, Rossmann MG. Visualization of the externalized VP2 N terminus of infectious human parvovirus B19. J Virol. 2008 Aug;82(15):7306-12.
8. Halder S, Nam HI, Govindasamy L, et al. Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids. J Virol. 2013;87(9):5128-5140.
9. Young N, Harrison M, Moore J, Mortimer P, Humphries RK. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest. 1984 Dec;74(6):2024-32.
10. Bönsch C, Kempf C, Ros C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol. 2008 Dec;82(23):11784-91.
11. Harbison CE, Chiorini JA, Parrish CR. The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol. 2008 May;16(5):208-14.
12. Quattrocchi S, Ruprecht N, Bönsch C, Bieli S, Zürcher C, Boller K, Kempf C, Ros C. Characterization of the early steps of human parvovirus B19 infection. J Virol. 2012 Sep;86(17):9274-84.
13. Chen AK, Kleihoeker S, Qiu J. Productive parvovirus B19 infection of primary human erythroid progenitor cells at hypoxia is regulated by STAT3 and MEK signaling but not HIFα. PLoS Pathog. 2011 Jun;7(6):e1002088.
14. Nunoue T, Okochi K, Mortimer PP, Cohen BJ. Human parvovirus (B19) and erythema infectiosum. J Pediatr. 1985 Jul;107(1):38-40.
15. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. Experimental parvoviral infection in humans. J Infect Dis. 1985 Aug;152(2):257-65.
16. Lin KH, You SL, Chen CJ, Wang CF, Yang CS, Yamazaki S. Seroepidemiology of human parvovirus B19 in Taiwan. J Med Virol. 1999 Feb;57(2):169-73.
17. Takano T, Yamada K. Quantitation of human parvovirus B19 DNA by real-time polymerase chain reaction. Pediatr Int. 2007 Aug;49(4):459-62.
18. Satake M, Hoshi Y, Taïra R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion. 2011 Sep;51(9):1887-95.
19. Anderson LJ, Hurwitz ES. Human parvovirus B19 and pregnancy. Clin Perinatol. 1988 Jun;15(2):273-86.
20. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004 Jul;24(7):513-8.
21. Lassen J, Jensen AK, Bager P, Pedersen CB, Panum I, Nørgaard-Pedersen B, Aaby P, Wohlfahrt J, Melbye M. Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: a population-based case-control study. Am J Epidemiol. 2012 Nov 1;176(9):803-7.
22. Forestier F, Tissot JD, Vial Y, Daufos F, Hohlfeld P. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Hematol. 1999 Mar;104(4):925-7.
23. Peters MT, Nicolaides KH. Cordocentesis for the diagnosis and treatment of fetal parvovirus infection. Obstet Gynecol. 1990 Mar;75(3 Pt 2):501-4.
24. Lassen J, Bager P, Wohlfahrt J, Böttiger B, Melbye M. Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring. Int J Epidemiol. 2013 Aug;42(4):1070-6.
25. Lejeune A, Cremer M, von Bernuth H, Edelmann A, Modrow S, Bührer C. Persistent pure red cell aplasia in dicygotic twins with persistent congenital parvovirus B19 infection-remission following high dose intravenous immunoglobulin. Eur J Pediatr. 2014 Dec;173(12):1723-6.
26. Beigi RH, Wiesendfeld HC, Landers DV, Simhan HN. High rate of severe fetal outcomes associated with maternal parvovirus b19 infection in pregnancy. Infect Dis Obstet Gynecol. 2008;2008:524601.
27. Markenson GR, Yancey MK. Parvovirus B19 infections in pregnancy. Semin Perinatol. 1998 Aug;22(4):309-17.